Omnichannel engagement in pharma: why strategy still fails at ground level

Omnichannel engagement pharma has become a standard ambition across the industry. It appears in transformation roadmaps, investor updates and brand plans. On paper, most pharmaceutical organisations now claim to operate with connected journeys and coordinated touchpoints. In reality, many are still dealing with fragmented execution, duplicated efforts and inconsistent experiences for healthcare professionals.

The intention is clear: meet stakeholders where they are, combine digital and in-person interactions intelligently, and use data to improve relevance. The difficulty lies in making that vision work in everyday practice.

The theory sounds simple. The reality is not.

In theory, omnichannel engagement means aligning field visits, remote detailing, webinars, congress presence, email communications and medical information services into a coherent experience. Each interaction should build on the previous one. Nothing should feel random.

Now consider a typical scenario.

A cardiologist attends a sponsored webinar on a new therapy. Two days later, she receives a promotional email repeating the same headline messages. The following week, a representative visits and delivers a standard detailing aid without referencing either the webinar or the email. From the company’s perspective, three coordinated touchpoints have been delivered. From hers, it feels repetitive and disconnected.

This is where the gap between strategy and execution becomes visible.

Silos are not just structural. They are behavioural.

Most pharma companies have already reorganised around customer-centric principles. They have cross-functional committees, shared dashboards and transformation programmes. Yet silos persist, often in subtler forms.

Marketing may design digital campaigns based on segmentation models and engagement scores. Sales teams operate with territory pressure and face-to-face targets. Medical affairs focuses on scientific integrity and compliance. Each function is legitimate in its priorities. The problem is that alignment is often theoretical rather than operational.

If a sales representative is measured primarily on call frequency, digital orchestration becomes secondary. If marketing is rewarded for email open rates, content may be optimised for clicks rather than long-term relationship building. Incentives quietly shape behaviour, sometimes more than strategy documents ever will.

Data exists. Integration is another matter.

Few organisations today lack data. The issue is not scarcity but fragmentation.

Customer relationship management systems track visits. Marketing platforms record email performance. Event systems capture webinar attendance. In some cases, real-world evidence and prescription trends are layered on top.

But are these insights genuinely unified? Can a field rep easily see that a particular consultant engaged deeply with a specific piece of content last week? Can marketing adjust follow-up communications based on the outcome of a recent scientific exchange?

Often, the answer is no.

Without a reliable, shared view of the customer, personalisation becomes superficial. Messages are technically segmented but not truly contextual. That difference is noticeable to healthcare professionals.

Compliance: necessary discipline, hidden constraint

No discussion about engagement in pharma can ignore regulation. The UK environment, shaped by the ABPI Code and strict data protection standards, requires caution and rigour. This is entirely appropriate.

However, compliance can unintentionally slow coordination. Content approval cycles may not align with campaign timing. Data usage restrictions can limit experimentation. Teams may avoid innovative approaches simply because the internal process feels complex.

Over time, this fosters conservatism. Omnichannel plans become structured but rigid. True responsiveness, which is central to meaningful engagement, is harder to achieve.

The human side of resistance

Technology is rarely the main barrier. Culture is.

Field teams may perceive digital channels as competition rather than support. Marketing teams may feel their work is diluted when adapted across multiple formats. Medical teams may be wary of being drawn too closely into promotional orchestration.

Change requires more than new tools. It requires clarity about roles and reassurance about value.

When representatives understand that digital touchpoints warm up conversations rather than replace them, adoption improves. When medical affairs sees that coordinated engagement enhances scientific exchange rather than commodifies it, collaboration becomes easier.

Without that shared understanding, omnichannel remains a corporate initiative rather than a lived practice.

What effective execution actually looks like

When strategy and execution are genuinely aligned, the difference is subtle but powerful.

A healthcare professional attends a virtual advisory board. The insights gathered inform tailored follow-up content. The next field visit references specific discussion points raised during the meeting. A subsequent email offers a deeper dive into a question the clinician expressed interest in.

Each interaction feels connected. Not because there are more touchpoints, but because there is continuity.

This level of coordination requires disciplined planning and transparent communication across functions. It also requires a willingness to adjust based on feedback rather than sticking rigidly to pre-set campaign calendars.

Rethinking metrics

One of the quiet drivers of misalignment is measurement.

If success is defined by volume, more emails will be sent. If success is defined by reach, more channels will be added. Neither automatically improves engagement quality.

Organisations that close the execution gap often revisit their KPIs. They ask harder questions. Did this interaction prompt a meaningful scientific discussion? Did it lead to a change in understanding? Did it support better patient care?

These outcomes are more difficult to measure than open rates or click-through percentages. But they are far more aligned with long-term credibility.

The role of technology, realistically assessed

Advanced platforms can support orchestration, content personalisation and performance tracking. Some companies turn to specialised ecosystems, including solutions such as Xpeer, to structure more integrated digital engagement across stakeholders.

Yet no platform can compensate for unclear ownership or inconsistent incentives. Technology amplifies existing behaviours. If collaboration is weak, digital systems will simply scale that weakness.

Before investing in new tools, organisations should examine whether their operating model genuinely supports coordination. Are planning cycles shared? Are objectives aligned? Is data governance robust and trusted?

Without these foundations, even the most sophisticated system will underdeliver.

Bringing it back to the stakeholder

It is easy to focus on internal alignment and forget the external perspective. Ultimately, omnichannel success is judged by the person receiving the interaction.

Healthcare professionals are selective with their attention. They prioritise information that is concise, relevant and timely. They expect continuity, not repetition. If pharmaceutical engagement adds administrative burden or cognitive overload, it will be filtered out.

A practical test is simple: if you mapped all touchpoints from the clinician’s perspective over the past three months, would they tell a coherent story? Or would they look like isolated initiatives stitched together after the fact?

That question often reveals more than any internal dashboard.

Turning omnichannel into a capability, not a slogan

The companies that make progress treat omnichannel not as a campaign theme but as a core capability.

They invest in data quality, not just data volume. They align incentives across functions. They encourage feedback loops from field teams to marketing and medical. They accept that iteration is necessary.

Most importantly, senior leadership reinforces consistency. When leaders prioritise coordinated engagement in resource allocation, performance reviews and internal communication, it becomes embedded in behaviour.

A more grounded path forward

The ambition behind omnichannel engagement in pharma is valid. Stakeholders deserve coherent, respectful interactions. Digital maturity among healthcare professionals continues to rise, and expectations are shaped by experiences far beyond the healthcare sector.

The gap between strategy and execution does not stem from a lack of intelligence or effort. It stems from complexity, legacy structures and cautious cultures. Closing it requires discipline rather than slogans.

When alignment extends beyond presentation slides into incentives, systems and daily routines, omnichannel engagement moves from aspiration to practice. And when that happens, the industry is better positioned to build trust, support informed decision-making and ultimately contribute to improved patient outcomes.